April 29, 2022
1 min watch
Save
Video: SGLT2 inhibitors ‘gaining momentum’ in heart failure treatment
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Lynne Warner Stevenson, MD, discusses new guidelines regarding the use of SGLT2 inhibitors from the American College of Cardiology Scientific Session.
Stevenson, professor of medicine (cardiology) at Vanderbilt University Medical Center, said SGLT2 inhibitors are now a level 1 recommendation for HF with reduced ejection fraction and level 2-A for HF with preserved ejection fraction.
Stevenson, who also speculated on the potential impact on renal function, said it could be one of the main reasons the inhibitors are effective on a wide range of patient populations.
Reference:
- Heidenreich PA, et al. AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Presented at: American College of Cardiology Scientific Session; April 2-4, 2022; Washington, D.C
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Stevenson reports no relevant financial disclosures.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.